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ABSTRACT
The T cell immunoglobulin and mucin domain 3 (Tim-3) is a plasma membrane-
associated receptor which is involved in a variety of biological responses in human 
immune cells. It is highly expressed in most acute myeloid leukaemia (AML) cells and 
therefore may serve as a possible target for AML therapy. However, its biochemical 
activities in primary human AML cells remain unclear. We therefore analysed the 
total expression and surface presence of the Tim-3 receptor in primary human AML 
blasts and healthy primary human leukocytes isolated from human blood. We found 
that Tim-3 expression was significantly higher in primary AML cells compared to 
primary healthy leukocytes. Tim-3 receptor molecules were distributed largely on the 
surface of primary AML cells, whereas in healthy leukocytes Tim-3 protein was mainly 
expressed intracellularly. In primary human AML blasts, both Tim-3 agonistic antibody 
and galectin-9 (a Tim-3 natural ligand) significantly upregulated mTOR pathway 
activity. This was in line with increased accumulation of hypoxia-inducible factor 
1 alpha (HIF-1`) and secretion of VEGF and TNF-`. Similar results were obtained 
in primary human healthy leukocytes. Importantly, in both types of primary cells,  
Tim-3-mediated effects were compared with those induced by lipopolysaccharide 
(LPS) and stem cell factor (SCF). Tim-3 induced comparatively moderate responses 
in both AML cells and healthy leukocytes. However, Tim-3, like LPS, mediated the 
release of both TNF-` and VEGF, while SCF induced mostly VEGF secretion and did 
not upregulate TNF-` release.
INTRODUCTION
The immune receptor T-cell immunoglobulin 
and mucin domain 3 (Tim-3) is involved in a variety 
of leukocyte biological responses [1]. In T cells it 
mainly mediates the inhibition of Th1 responses, while 
in dendritic cells it has a pro-inflammatory effect. In 
monocytes and macrophages Tim-3 is involved in 
phagocytosis [1]. However, in myeloid leukaemia cell 
lines Tim-3 was shown to induce a moderate growth 
factor/pro-inflammatory responses, similar to those 
observed by myeloid cell growth factors (for example 
stem cell factor – SCF) [2, 3].
Interestingly, Tim-3 is highly expressed in leukaemia 
cells, especially in T-cell lymphocytic leukaemia cells as 
well as acute myeloid leukaemia (AML) cells [4–6]. In 
leukaemic T cells Tim-3 agonists induce programmed cell 
death pathways, while in AML cells this does not seem to 
be the case [1, 6]. However, the biochemical mechanisms 
involved in the activation of human myeloid cells and, 
especially, in AML cells, are largely unknown.
Tim-3 is considered as one of the possible AML 
antigens, since malignant AML cells preserve the ability 
to express the SCF receptor (Kit or CD117) as well as 
Tim-3 [5, 7]. In contrast, myeloid stem cells only express 
Kit receptors but not Tim-3 [5]. Conversely, in most cases, 
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mature myeloid cells express Tim-3 but not Kit receptors 
[5, 8]. Despite these differences in cell surface presence, 
total expression levels of Tim-3 in AML cells are also 
significantly increased compared to healthy leukocytes [5].
In myeloid cell lines and primary myeloid 
hematopoietic cells Tim-3 is known to mediate the 
activation of NF-kB transcription factor and TNF-α 
secretion [3]. Furthermore, in AML cell lines, Tim-3 
moderately activates the mammalian target of rapamycin 
(mTOR, a master regulator of myeloid cell translational 
pathways). This results in activation of the hypoxia-
inducible factor 1 (HIF-1) transcription complex, which 
upregulates glycolysis and expression/secretion of the 
pro-angiogenic vascular endothelial growth factor (VEGF) 
[2]. However, the differential effects of Tim-3 in ex vivo 
systems such as primary human AML cells versus healthy 
human leukocytes have not yet been elucidated.
In the present study, we therefore analysed both the 
total and cell surface expressions of the Tim-3 receptor in 
primary human AML blasts and healthy primary human 
leukocytes obtained from peripheral blood (buffy coats). 
We found that, in primary AML cells, Tim-3 expression is 
much higher compared to primary healthy leukocytes. We 
also observed that Tim-3 receptor molecules were mostly 
expressed on the surface of primary AML cells, while the 
majority of Tim-3 protein remained inside primary human 
healthy leukocytes. In primary human AML blasts (AML-
PB001F), Tim-3 agonistic antibody as well as galectin-9 
(one of the natural ligands of Tim-3) induced activation of 
the mTOR pathway (by mTOR-dependent phosphorylation 
of p70 S6 kinase 1 (p70 S6K1) and eIF4E-binding 
protein-1 (eIF4E-BP1)). This was in line with HIF-1 
activation and increased secretion of VEGF and TNF-α. 
Similar results were obtained in primary human leukocytes 
isolated from buffy coats obtained from the blood of 
healthy donors. Importantly, in both types of primary 
cells, the effects were compared with those induced by 
lipopolysaccharide (LPS, a Gram-negative bacteria-derived 
toll-like receptor 4 (TLR4) ligand) and SCF (Kit ligand). 
In primary AML cells SCF induced the strongest biological 
response, whereas LPS displayed comparatively greater 
effects on primary human leukocytes. Tim-3 in both cases 
induced moderate cellular responses. However, although 
Tim-3, like LPS, triggered the release of both TNF-α and 
VEGF, SCF induced mostly VEGF secretion and did not 
significantly impact the TNF-α release.
RESULTS
Primary human AML blasts and healthy 
leukocytes express the Tim-3 immune receptor
Our recent work demonstrated that Tim-3 mediates 
the activation of mTOR via phosphorylation of its S2448 
residue and HIF-1 signalling in human AML cell lines 
[2]. We therefore sought to understand the expression and 
behaviour of this receptor in primary human AML cells 
(AML-PB001F primary mononuclear blasts were used) 
in comparison with healthy whole blood primary human 
leukocytes (PLs).
In order to compare the expression and, more 
importantly, re-distribution of Tim-3 in the cells we 
analysed its total amount and cell surface presence 
using in-cell Western and in-cell assay respectively. We 
found that both primary AML blasts and healthy whole 
blood leukocytes expressed Tim-3 as detected by in-cell 
Western and in-cell assay (Figure 1A and 1B). However, 
in AML cells most of the receptor molecules were 
externalised, whereas in healthy PLs only around 30% 
were present on the surface, clearly indicating that the 
vast majority of Tim-3 protein was stored inside the cell 
(Figure 1A and 1B), where Tim-3 function is unknown. 
These findings confirm that AML cells express more 
Tim-3 protein compared to healthy leukocytes and, 
importantly, AML cells retain almost all Tim-3 receptor 
molecules on their cell surface.
Tim-3 triggers activation of the mTOR pathway 
and HIF-1 signalling in primary AML cells and 
primary healthy human leukocytes (PLs)
Given the high expression/externalisation levels of 
Tim-3 protein in primary human AML cells compared 
to PLs we sought to obtain evidence on differences 
in receptor downstream activities. We found that, in 
primary AML cells, mTOR S2448 phosphorylation was 
substantially increased upon exposure to SCF as well as 
to anti-Tim-3 antibody stimulation (about 50% of SCF-
induced effect), while LPS displayed a weaker ability 
to upregulate the intracellular levels of phospho-S2448 
mTOR. The same pattern was observed for PI-3K activity 
(Figure 2A). Activity of LPS can be explained by the 
low TLR4 expression levels reported by the supplier for 
AML-PB001F primary human AML cells. These results 
were in line with mTOR activity levels monitored based 
on intracellular amounts of phospho-T389 p70 S6 K1 and 
phospho-S65 eIF4E-BP1 (Figure 2A).
Both proteins are phosphorylated at the indicated 
positions by the mTOR kinase complex [9]. All the 
stimuli demonstrated the ability to upregulate HIF-1α 
accumulation; anti-Tim-3 was the weakest inducer 
(Figure 2B) which is consistent with the observations 
made in cell lines. Stronger LPS-induced effects in this 
case were due to the fact that LPS-dependent HIF-1α 
accumulation, unlike the one triggered by both SCF and 
anti-Tim-3, did not solely depend on mTOR activation. 
LPS-induced TLR4-mediated HIF-1α accumulation is 
known to be jointly triggered through a redox-dependent 
mechanism, as well as mTOR and mitogen-activated 
protein (MAP) kinase signalling cascades [10, 11]. 
Therefore, the observed effects were achieved jointly 
via activation of all three pathways, the intensities of 
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which were comparable with mTOR-dependent processes 
following exposure to SCF (Figure 2A and 2B). Total 
Tim-3 levels were not affected by any of the above 
stimuli, while in AML cell lines SCF and Tim-3 receptor 
activation upregulated total Tim-3 expression (Figure 2B). 
Importantly, as with LPS, anti-Tim-3 antibody was able 
to upregulate secretion of both TNF-α and VEGF, while 
SCF mostly upregulated VEGF production and did not 
dramatically change TNF-α secretion level (Figure 2B).
Galectin-9, a natural Tim-3 ligand [2, 5], 
demonstrated the ability to upregulate both mTOR 
kinase activity and HIF-1α accumulation in primary 
AML-PB001F blasts at levels comparable to those seen 
with anti-Tim-3. This suggests similar activities of both 
agonistic ligands (Figure 3A and 3B).
In primary human healthy leukocytes the effects 
of anti-Tim-3 antibody were similar to those observed in 
AML cells. However, in healthy PLs LPS (and not SCF) 
was the most powerful cell activator (Figure 4A and 4B). 
This is probably due to the fact that healthy leukocytes 
contain more cells which express TLR4 than those that 
express Kit receptors. The effects of anti-Tim-3 antibody 
in this case were similar to those of SCF and slightly 
lower than the effects of anti-Tim-3 detected in primary 
human AML blasts (Figure 4A and 4B). Isotype control 
(IgG 2a) antibody [2] was also incubated with all the cell 
types studied and did not induce any effect in cell lines or 
primary leukocytes (data not shown).
Interestingly, background intracellular levels of 
phospho-S2448 mTOR, HIF-1α and Tim-3 proteins as well 
as VEGF, but not PI-3K activity and secreted TNF-α, were 
significantly higher in AML blasts compared to healthy 
PLs (a quantitative breakdown is shown in Figure 5A–5H). 
These findings confirm that the proteins discussed above 
are used by leukaemia cells on a permanent basis more 
than by healthy leukocytes.
DISCUSSION
The immune receptor Tim-3 is expressed in healthy 
human hematopoietic cells and, despite numerous studies, 
its functional role is still a subject for intensive research 
[6]. Recent evidence demonstrated that the Tim-3 receptor 
is highly expressed and externalised in human AML cells 
[5, 7]. Importantly, progenitor hematopoietic cells do not 
express Tim-3 receptors while they produce substantial 
Figure 1: Comparative analysis of Tim-3 expression and surface presence in primary human AML cells and healthy 
leukocytes. 300,000 per well of AML-PB001F primary human AML cells A. and 1,500,000 per well of healthy PLs B. were subjected to 
in-cell Western (ICW) in order to detect total Tim-3 expression. The Tim-3 surface presence was analysed by in-cell assay (ICA). For 
healthy PLs, 1,500,000 cells per well were necessary to properly visualise Tim-3 receptor on the cell surface. Fluorescence values obtained 
for AML cells and healthy PLs were divided by respective cell number (300,000 or 1,500,000) and used for calculations. Images are from 
one experiment representative of three which gave similar results. Quantitative data are shown as means ± SEM of at least three individual 
experiments; **p < 0.01 vs. control.
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amounts of Kit (SCF) receptors. Mature healthy leukocytes 
generally lose their ability to express the Kit receptor 
but start expressing Tim-3 protein. Malignant AML 
cells express both receptors and thus their growth and 
proliferation depend on SCF while the biological activity 
of Tim-3 remains unclear [5]. It was reported that, in 
primary dendritic cells, Tim-3 induces TNF-α production 
through the NF-kB transcription factor [1, 3]. Our recent 
studies demonstrated that Tim-3 mediates activation of 
the PI3K/mTOR pathway in human AML cell lines [2]. 
Figure 2: Anti-Tim-3 agonistic antibody induces mTOR activity, HIF-1α accumulation as well secretion of VEGF and 
TNF-α in primary human AML cells. AML-PB001F cells were exposed for 4 h for the indicated concentrations of anti-Tim-3, LPS 
and SCF, followed by analysis of PI-3K/mTOR pathway activity A. HIF-1α accumulation and release of VEGF and TNF-α B. Images are 
from one experiment representative of four which gave similar results. Quantitative data are shown as means ± SEM of four individual 
experiments; *p < 0.05; **p < 0.01 vs. control.
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However, it was not clear whether similar effects take 
place in primary human AML cells in comparison with 
healthy primary leukocytes, since activating both mTOR 
pathways and TNF-α production utilize both growth factor 
and inflammatory mediator-like responses.
We observed that primary AML cells generate 
more Tim-3 protein compared to healthy leukocytes, 
including cell surface protein expression. Only about 30% 
of Tim-3 molecules were externalised in primary healthy 
leukocytes, while almost all Tim-3 protein was present on 
the cell surface of primary AML cells. This could have 
impact on differences in activity of the protein in terms of 
its ability to mediate ligand-induced activation of mTOR, 
HIF-1α accumulation and cytokine releases. Our results 
suggest that Tim-3 mediates ligand-induced activation 
of the mTOR pathway, which involves upregulation of 
Figure 3: Anti-Tim-3 and galectin-9 induce similar responses in primary human AML cells. AML-PB001F cells were 
exposed for 4 h for the indicated concentrations of anti-Tim-3 and galectin-9 followed by analysis of PI-3K/mTOR pathway activity A. and 
HIF-1α accumulation B. Images are from one experiment representative of three which gave similar results. Quantitative data are shown as 
means ± SEM of three individual experiments; *p < 0.05; **p < 0.01 vs. control.
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phospho-S2448 mTOR levels, phosphorylation of p70 
S6K1(T389) and eIF4E-BP1 (S65), accumulation of 
HIF-1α protein and secretion of TNF-α and VEGF. It is 
however, clear that the effects are moderate and are weaker 
than those induced by LPS or SCF, a classic inflammatory 
mediator and hematopoietic growth factor, respectively.
In AML cells, SCF displayed the highest biological 
activity while LPS effects were stronger in healthy whole 
blood PLs. These differences are due to differential 
expression of TLR4 and Kit receptors in healthy and 
malignant leukocytes. SCF-induced responses in healthy 
PLs are likely to involve both direct and indirect effects. 
Figure 4: Anti-Tim-3 induces mTOR activity, HIF-1α accumulation as well secretion of VEGF and TNF-α in primary 
human healthy leukocytes. PLs were exposed for 4 h for the indicated concentrations of anti-Tim-3, LPS and SCF followed by 
analysis of PI-3K/mTOR pathway activity A. HIF-1α accumulation and release of VEGF and TNF-α B. Images are from one experiment 
representative of four which gave similar results. Quantitative data are shown as means ± SEM of four individual experiments; *p < 0.05; 
**p < 0.01 vs. control.
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Figure 5: Comparative quantitative analysis of mTOR/HIF-1 pathway components as well as VEGF/TNF-α secretion 
in primary human AML cells and healthy human PLs. Protein levels were compared based on the indicated type of detection. 
A. pS2448 mTOR intracellular levels were detected by ELISA, normalised against total cellular protein and compared (results were 
statistically validated). B, C. and D. – Levels of p70 S6K1, eIF4E-BP1 and HIF-1α protein were detected by Western blot (WB), quantitated 
and normalised against respective actin values before comparison and statistical validation of the results. E. PI-3K activity levels were 
measured by colorimetric assay (CA), F. – Intracellular levels of Tim-3 were detected by in-cell Westerns (ICW). Fluorescence values 
obtained for healthy PLs and AML cells and were divided by respective cell number (1,500,000 or 300,000, see Figure 1) and used for 
comparison (the value in PLs was considered as 100%). Similar results were obtained when comparing Tim-3 values in AML cells and 
healthy PLs obtained by Western blot and normalised against actin G. TNF-α and H. VEGF levels were measured in the medium by ELISA 
and the amounts per 106 cells were compared and statistically validated. Data was obtained from 3–6 individual experiments, which gave 
similar results. Quantitative data are shown as means ± SEM; *p < 0.05; **p < 0.01; ***p < 0.01 vs. control.
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Several types of leukocytes express Kit receptors. 
This includes hematopoietic stem cells, multipotent 
progenitors, common myeloid progenitors, common 
lymphoid progenitors, megakaryocytes, myeloblasts, 
small lymphocytes, eosinophils, NK cells and dendritic 
cells [8, 12, 13]. Altogether, this amounts to more than 
5–10% of blood leukocytes. SCF is known to trigger 
IL-6 release in primary cells [14] and we have also 
observed a clear increase in IL-6 secretion in healthy 
PLs exposed to 100 ng/ml SCF for 4 h (data not shown). 
IL-6 is known to upregulate VEGF release [15], which 
is a HIF-1-dependent process [16]. These effects could 
contribute to both HIF-1α accumulation and VEGF release 
in addition to SCF (primary stimulus, see Figure 4 for 
more details).
Although Tim-3 ligands are known to trigger 
programmed death of T cells and demonstrate 
downregulatory properties (especially malignant types, 
[1], 55–86% of all leukocytes are myeloid cells. Therefore, 
phenotypically, we observed the response of the vast 
majority of the total cell pool, indicating that the observed 
effects were likely to be derived from myeloid cells.
Intriguingly, the background levels of 
phospho-S2448 mTOR, HIF-1α, Tim-3 as well as p70 
S6K1/eIF4E-BP-1 proteins are significantly higher in 
non-treated AML cells compared to resting healthy PLs 
(see Figure 5 for details). This phenomenon is especially 
applicable to the HIF-1α accumulation which is strong in 
non-treated AML cells and almost undetectable (detectable 
only upon loading around 140,000 cell per well) in 
healthy PLs. This observation becomes more intriguing 
in light of recently reported contribution of HIF-1 to 
Tim-3 expression [17]. Respectively, VEGF but not TNF-α 
secretions were significantly higher in non-treated AML 
cells compared to healthy PLs. Importantly, background 
levels of the PI-3K activity were very similar in AML 
cells and healthy PLs. This suggests that the increased 
background levels of pS2448 mTOR in primary AML cells 
could be due to increased constitutive phosphorylation as 
reported, for example, for the LAD2 mast cell line [18, 
19]. LAD2 mast cells are also derived from the myeloid 
lineage, and were obtained from a 44-year-old male 
patient suffering from mastocytosis. Analysis of bone 
marrow biopsies/aspirates showed results consistent with 
an aggressive form of mast cell leukemia/sarcoma [20]. 
This suggests that the mTOR/HIF-1/VEGF pathway, but 
not inflammatory TNF-α, is used permanently by AML 
cells compared to healthy PLs.
Taken together, our findings indicate that Tim-3 in 
primary leukocytes, both healthy and malignant AML 
cells, displays moderate properties of an inflammatory 
receptor with additional growth factor (mTOR activation) 
and pro-angiogenic (VEGF release) activities (a summary 
of the biochemical activities of Tim-3 in AML cells 
is provided in Figure 6). Although the mTOR/HIF-1 
pathway is triggered by both LPS and SCF, we only 
observed a significant increase in TNF-α/VEGF secretion 
(production of both factors is regulated by mTOR 
[21, 22]) following LPS stimulation. SCF induced mostly 
VEGF release and did not trigger the production of pro-
inflammatory TNF-α. However, highly increased levels of 
Tim-3 protein in AML cells compared to those in healthy 
PLs did not result in higher specific biochemical activity 
of the receptor.
Currently, Tim-3 is being considered as a target 
antigen for anti-leukaemia therapy including T-cell 
leukaemia and AML [5] as well as to reverse T cell 
exhaustion and restore anti-tumour immunity [23]. In 
addition to the current knowledge, our findings suggest 
that Tim-3 is more abundant on the surface of AML cells 
compared to healthy leukocytes. This, together with the 
moderate biochemical activities associated with Tim-3 
activation, is encouraging since it highlights a relatively 
easy way of recognition and selective targeting of human 
AML cells.
MATERIALS AND METHODS
Materials
RPMI-1640 medium, foetal calf serum and 
supplements, P. aeruginosa LPS, were purchased from 
Sigma (Suffolk, UK). Maxisorp™ microtitre plates 
were obtained either from Nunc (Roskilde, Denmark) 
or kindly provided by Oxley Hughes Ltd (London, UK). 
Mouse monoclonal antibodies to HIF-1α, mTOR and 
β-actin as well as rabbit polyclonal antibodies against 
phospho-S2448 mTOR were purchased from Abcam 
(Cambridge, UK). Antibodies against phospho-T389 p70 
S6 kinase 1 (p70 S6K1), total and phospho-S65 eukaryotic 
initiation factor 4E binding protein 1 (eIF4E-BP1) 
antibodies were obtained from Cell Signaling Technology 
(Danvers, MA USA). Goat anti-mouse and goat anti-rabbit 
fluorescence dye-labelled antibodies were obtained from 
Li-Cor (Lincoln, Nebraska USA). ELISA-based assay 
kits for the detection of VEGF, TNF-α and IL-6 were 
purchased from Bio-Techne (R&D Systems, Abingdon, 
UK). All other chemicals were of the highest grade of 
purity and available commercially unless otherwise stated.
Primary human AML cells
Primary human AML mononuclear blasts (AML-
PB001F, newly diagnosed/untreated) were purchased from 
AllCells (Alameda, CA, USA) and handled in accordance 
with manufacturer’s instructions. Cells from two different 
patients were analysed.
Primary human leukocytes obtained from 
healthy donors (buffy coats)
Primary human leukocytes were obtained from 
buffy coat blood (which originated from healthy donors 
undergoing routine blood donation). The buffy coat 
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blood was purchased from the National Health Blood 
and Transfusion Service (NHSBT, UK) following 
ethical approval (REC reference: 12/WM/0319). 
Mononuclear-rich leukocytes were obtained by Ficoll-
density centrifugation according to the manufacturer’s 
protocol. Cell numbers were determined using a 
haemocytometer and diluted accordingly with HEPES-
buffered Tyrode’s solution before treatment as indicated 
below.
Stem cell factor
Human SCF protein was produced in E.Coli and 
purified in accordance with published protocols [24].
Western blot analysis
Expressions of HIF-1α, total and phospho-T389 
p70 S6K1, as well as total and phospho-S65 eIF4E-BP1 
were determined by Western blot analysis and compared 
to β-actin in order to determine equal protein loading, 
as previously described [25]. Li-Cor goat secondary 
antibodies, conjugated with fluorescent dyes, were 
employed according to the manufacturer’s protocol 
in order to visualise detected proteins (using a Li-Cor 
Odyssey imaging system). Following Western blot 
detection of phospho-T389 p70S6K1 and phospho-S65-
eIF4E-BP1, membranes were stripped using a ReBlot™ 
Plus Kit (Chemicon International) according to the 
Figure 6: A schematic summary of ligand-induced Tim-3-mediated biological responses in healthy primary human 
leukocytes and primary human AML cells. 
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manufacturer’s protocol. Membranes were then blocked 
and scanned using a Li-Cor Odyssey imaging system to 
make sure that stripping was successfully completed. 
Then membranes were re-probed with antibodies in order 
to detect the total amounts of p70S6K1 and eIF4E-BP1. 
Western blot data were quantitatively analysed using 
Odyssey software and values were normalised against 
respective β-actin bands.
Detection of phospho-S2448 mTOR in cell lysates 
by ELISA
Phosphorylation of mTOR was analysed by ELISA as 
recently described [25]. Briefly, 96-well ELISA plates were 
coated with mouse anti-mTOR antibodies and then blocked 
with 2% BSA. Cell lysates were then added to the wells 
and incubated at room temperature for 2 h under constant 
agitation. After extensive washing with Tris-Buffered 
Saline and Tween 20 (TBST) buffer, anti-phospho-S2448 
mTOR antibodies were added and plates incubated for 2 h 
at room temperature with constant agitation. After washing 
with TBST buffer plates were incubated with HRP-labelled 
goat anti-rabbit IgG (1:1000 dilution in TBST buffer). 
After 1 h incubation, plates were extensively washed using 
TBST and bound secondary antibodies were detected by 
the peroxidase reaction (ortho-phenylenediamine/H2O2).
In-cell western and in-cell assay
We employed a standard Li-Cor in-cell Western 
assay to analyse total Tim-3 expressions in primary 
human AML cells and healthy primary leukocytes (PLs). 
The in-cell assay was also applied to detect Tim-3 protein 
surface presence in the studied cells [2].
Detection of VEGF, TNF-α and IL-6 release
Concentrations of these cytokines released into the 
medium were analysed by ELISA (R&D Systems assay 
kits) according to the manufacturer’s instructions.
Analysis of phosphatidylinositol-3 kinase (PI-3K) 
activity
The activity of PI-3K was measured using a non-
radioactive assay based on the ability of the enzyme to 
phosphorylate its substrate as previously described [26].
Statistical analysis
Each experiment was performed at least three times 
and statistical analysis was conducted using a two-tailed 
Student’s t test. Statistical probabilities (p) were expressed 
as *, where p < 0.05, **, where p < 0.01 and *** when 
p < 0.001.
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